Group 1 - The company, Chao Yan Co., reported a revenue of approximately 254 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 2.9% [1] - The net profit attributable to shareholders of the listed company was approximately 88.94 million yuan, a year-on-year decrease of 3.66% [1] - The basic earnings per share were 0.21 yuan, reflecting a year-on-year decrease of 16% [1]

Core Viewpoint - Chao Yan Co., Ltd. (301602.SZ) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 254 million yuan, a year-on-year decrease of 2.90% [1] - The net profit attributable to shareholders was 88.94 million yuan, reflecting a year-on-year decrease of 3.66% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.19 million yuan, showing a slight decrease of 0.03% year-on-year [1] - Basic earnings per share stood at 0.21 yuan [1]

中国银河证券股份有限公司 关于汕头市超声仪器研究所股份有限公司 使用募集资金置换投入募投项目自筹资金 的核查意见 中国银河证券股份有限公司（以下简称"银河证券"或"保荐人"）作为汕头市 超声仪器研究所股份有限公司（以下简称"公司"或"超研股份"）首次公开发行股 票并上市的保荐人，根据《证券发行上市保荐业务管理办法（2025 修正）》《深圳证 券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作（2025 年修订）》《上市公司募集资金监管 规则》等有关规定，对超研股份使用募集资金置换投入募投项目自筹资金事项进行了 审慎核查，发表核查意见如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已完成首次 公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元，募集资金总额 为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不含税），公司实际募 集资金净额为人 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第二届董事会第十次会议，审议通过了《关于使用募集资金置换投入 募投项目的自筹资金的议案》，同意公司使用募集资金置换投入募投项目的自筹 资金。现将有关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司 首次公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已 完成首次公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元， 募集资金总额为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不 含税），公司实际募集资金净额为人民币 384,363,201.32 元，募集资金已于 2025 年 1 月 17 日划至公司指定账户。华兴会计师事务所（特殊普通合伙）对公司本 次公开发行股票的资金到位情况进行了审验，并于 2025 年 1 月 17 日出具了《验 资报告》（华兴验字〔2025〕2 ...

汕头市超声仪器研究所股份有限公司 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 汕头市超声仪器研究所股份有限公司（以下简称"公司"）第二届董事会第 十次会议于 2025 年 10 月 28 日以现场方式在汕头市龙江路 3 号汕头市超声仪器 研究所股份有限公司 1 楼会议室召开。此前公司于 2025 年 10 月 17 日以电子邮 件、微信、电话等方式向全体董事发出会议通知。 本次会议应出席董事 9 人，实际出席董事 9 人（其中：委托出席的董事人数 1 人），董事吴宏豪先生因公务无法亲自出席会议，委托董事周宏策先生出席会 议。公司部分高级管理人员列席了本次会议。会议由董事长李德来先生主持。本 次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中华人 民共和国证券法》等法律、法规、规范性文件和《公司章程》的相关规定。 证券代码：301602 证券简称：超研股份 公告编号：2025-048 2、审议通过《关于使用募集资金置换投入募投项目的自筹资金的议案》。 经审议，董事会认为：公司使用募集资金 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥69,929,018.69, a decrease of 31.07% compared to the same period last year[4] - Net profit attributable to shareholders was ¥20,499,021.09, down 40.69% year-on-year[4] - The basic earnings per share decreased by 44.44% to ¥0.05, while diluted earnings per share also fell by 44.44% to ¥0.05[4] - Total revenue for the current period is ¥253,606,900.34, a decrease of 2.16% from ¥261,170,540.28 in the previous period[18] - Net profit for the current period is ¥88,944,481.22, down 3.66% from ¥92,321,637.60 in the previous period[19] - The total comprehensive income for the current period is ¥89,342,559.55, a decrease from ¥92,491,503.99 in the previous period, reflecting a decline of approximately 3.7%[20] - Basic and diluted earnings per share for the current period are both ¥0.21, down from ¥0.25 in the previous period, representing a decrease of 16%[20] Assets and Liabilities - Total assets increased by 40.39% to ¥1,412,413,645.76 compared to the end of the previous year[4] - Current assets rose to ¥1,288,085,508.61, up 46.49% from ¥879,665,743.61 at the beginning of the period[16] - Total liabilities decreased to ¥110,843,896.09 from ¥135,377,063.86, a decline of 18.14%[17] - The company's equity increased significantly to ¥1,301,569,749.67 from ¥870,660,773.85, marking a growth of 49.43%[17] Cash Flow - Cash flow from operating activities for the year-to-date was ¥63,080,448.02, down 8.03%[4] - Cash inflow from operating activities totaled ¥323,042,024.98, an increase from ¥258,619,893.23 in the previous period, marking a growth of approximately 25%[21] - Net cash flow from operating activities is ¥63,080,448.02, down from ¥68,588,538.39 in the previous period, indicating a decline of about 8%[21] - Cash inflow from investment activities is ¥1,572,662,164.31, a decrease from ¥2,357,317,461.91 in the previous period, reflecting a decline of approximately 33%[22] - Net cash flow from investment activities is -¥23,375,488.23, worsening from -¥5,673,376.00 in the previous period[22] - Cash inflow from financing activities is ¥401,633,651.91, with cash outflow for dividend distribution and interest payments totaling ¥43,689,590.81[22] - The net increase in cash and cash equivalents for the current period is ¥375,611,864.95, compared to an increase of ¥58,039,045.05 in the previous period[22] - The ending balance of cash and cash equivalents is ¥578,090,968.49, significantly higher than ¥152,580,166.72 in the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,970[9] - The largest shareholder, Shantou Ultrasonic Asset Management Co., Ltd., holds 51.32% of shares, totaling 219,830,247 shares[9] - The second-largest shareholder, Shantou Municipal Government State-owned Assets Supervision and Administration Commission, holds 31.14% of shares, totaling 133,369,945 shares[9] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 84%[9] - The company has no preferred shareholders as of the reporting period[11] - There are no changes in the number of restricted shares for the major shareholders during the reporting period[12] - The total number of restricted shares at the end of the period is 369,975,714 shares[13] - The company plans to release some restricted shares in 2026, with specific dates for each shareholder[12] - The company has not reported any related party transactions among the top shareholders[10] Operational Insights - The company received government subsidies amounting to ¥5,359,015.20 during the reporting period[5] - Accounts receivable decreased by 50.92% to ¥23,717,480.19, primarily due to the collection of receivables[7] - Inventory increased by 37.66% to ¥149,882,508.32, mainly due to increased reserves of imported raw materials[8] - Research and development expenses for the current period were ¥39,350,225.93, an increase of 8.63% compared to ¥36,954,438.09 in the previous period[18] - The company reported a financial income of ¥18,894,748.75, which is an increase from ¥8,715,395.36 in the previous period[18] - The fair value change loss was recorded at -¥258,786.86, compared to a loss of -¥1,263,030.84 in the previous period, indicating an improvement[19] - The company has a strategic plan for future growth, focusing on market expansion and new product development[14] Audit Status - The company has not undergone an audit for the third quarter financial report[23]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company's overseas revenue accounted for 55.26%, benefiting from the depreciation of the RMB [3]. Market Activity - On October 28, the company's stock rose by 0.76%, with a trading volume of 57.19 million yuan and a turnover rate of 3.90%, bringing the total market capitalization to 10.755 billion yuan [1]. - The stock has seen a net outflow of 1.2384 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. Product and Innovation - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual meeting, focusing on pets, horses, and livestock, and engaged with industry experts on animal healthcare development [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the development of portable devices [2].

Core Viewpoint - Chao Yan Co., Ltd. has shown a stable financial performance with a notable increase in revenue and net profit, while also experiencing changes in shareholder structure and trading activity [1][2][3]. Financial Performance - For the first half of 2025, Chao Yan Co., Ltd. achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15% [2]. - The net profit attributable to shareholders reached 68.45 million yuan, marking an 18.5% increase compared to the previous period [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 16.65% to 22,300, while the average circulating shares per person increased by 19.98% to 2,456 shares [2]. - The top circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [3]. - Other notable new shareholders include Southern Zhongzheng 1000 ETF and Huaxia Zhongzheng 1000 ETF, indicating a shift in institutional holdings [3]. Trading Activity - On October 27, 2023, Chao Yan Co., Ltd. experienced a slight decline of 0.36% in stock price, with a trading volume of 50.21 million yuan [1]. - The financing buy-in amount for the day was 7.87 million yuan, with a net buy of 5.14 million yuan after repayments [1]. - The total margin trading balance reached 97.31 million yuan, with financing accounting for 6.68% of the circulating market value [1].

Core Viewpoint - Chao Yan Co., Ltd. has shown a slight increase in stock price and trading volume, with notable financing activities indicating investor interest and potential growth in the medical imaging and industrial non-destructive testing sectors [1][2]. Financing and Trading Activity - On October 24, Chao Yan Co., Ltd. experienced a stock price increase of 0.52% with a trading volume of 56.81 million yuan. The financing buy-in amounted to 3.27 million yuan, while the financing repayment was 4.04 million yuan, resulting in a net financing outflow of 0.77 million yuan. The total financing and securities balance reached 92.15 million yuan [1]. - The current financing balance is 91.98 million yuan, representing 6.30% of the circulating market value. In terms of securities lending, 1,200 shares were repaid with no shares sold on October 24, leading to a remaining securities lending balance of 6,800 shares valued at 170,100 yuan [1]. Company Performance - As of June 30, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period. The average circulating shares per person increased by 19.98% to 2,456 shares. For the first half of 2025, the company reported a revenue of 184 million yuan, reflecting a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [2]. - Since its A-share listing, Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends [3]. Shareholder Composition - As of June 30, 2025, the largest shareholder among the top ten circulating shareholders is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder. The second-largest is Southern Zhongzheng 1000 ETF with 514,500 shares, also a new shareholder. Hong Kong Central Clearing Limited is the fourth-largest shareholder with 470,000 shares, having increased its holdings by 21,600 shares compared to the previous period [3].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and medical device sectors, benefiting from the depreciation of the RMB and its recent listing as a new stock under the registration system [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [7]. - The main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to the parent company of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a shareholder count of 22,300, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [8]. Market Activity - On October 23, the company's stock rose by 2.26%, with a trading volume of 64.68 million yuan and a turnover rate of 4.50%, bringing the total market capitalization to 10.657 billion yuan [1]. - The stock has seen a net inflow of 3.62 million yuan from major investors today, accounting for 0.06% of the total, with the industry ranking at 9 out of 131 [4][5]. Product and Innovation - The company showcased its innovative veterinary medical imaging products at the 97th WVC annual conference, engaging with industry experts on the development of animal healthcare [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the capabilities of portable devices [2][3].